Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: An open, non-controlled, 8-week trial

Journal of Drugs in Dermatology

Volumn 12, Issue 8, 2013, Pages 882-887

  Silver, Shane ^a   Tuppal, Raj ^b   Gupta, Aditya K ^c   Clonier, Fabrice ^d   Olesen, Martin ^d   Leeder, Randy ^d   Taraska, Victoria ^e  

^a Dermadvances Research   (Canada)

^b Oshawa Clinic   (Canada)

^c MEDIPROBE RESEARCH INC   (Canada)

^d LEO PHARMA A S   (Denmark)

^e Winnipeg Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIUM; CORTICOTROPIN; CREATININE; HYDROCORTISONE;

ABDOMINAL PAIN; ADRENAL SUPPRESSION; ADULT; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; BODY SURFACE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM HOMEOSTASIS; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CORTICOTROPIN TEST; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GEL; HELICOBACTER INFECTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERHIDROSIS; HYPERTENSION; HYPOCALCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMPETIGO; LIMIT OF QUANTITATION; MALE; MULTICENTER STUDY; NIGHT SLEEP; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PSORIASIS VULGARIS; SUSPENSION; SYSTEMIC THERAPY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS;

ADMINISTRATION, CUTANEOUS; ADULT; BETAMETHASONE; CALCITRIOL; CALCIUM; CREATININE; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; PSORIASIS; SEVERITY OF ILLNESS INDEX; SUSPENSIONS; TIME FACTORS;

EID: 84882420132     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. McCormack PL. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs. 2011;71:709-30.
2. Devaux S, Castela A, Archier E et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26 Suppl 3:61-7.
3. Menter A, Gold LS, Bukhalo M et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013;12:92-8.
4. Kragballe K, Iversen L. Calcipotriol. A new topical antipsoriatic. Dermatol. Clin. 1993;11:137-41.
5. FDA. Diprosone® ointment product information. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2001/17691s19lbl.pdf. October 3, 2001.
6. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol. 2002;3:141-7.
7. Weston WL, Fennessey PV, Morelli J et al. Comparison of hypothalamuspituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-5.
8. Hengge UR, Ruzicka T, Schwartz RA et al. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 2006;54:1-15.
9. Bourke JF, Berth-Jones J, Iqbal SJ et al. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol. 1993;129:74-6.
10. FDA. Cortrosyn® product information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2002/16750slr018ltr.pdf. November 5, 2002.
11. Fleming C, Ganslandt C, Guenther L et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20:465-71.
12. Langley RG, Gupta A, Papp K et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology. 2011;222:148-56.
13. Berth-Jones J, Bourke JF, Iqbal SJ et al. Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol. 1993;129:411-4.
14. Kirkland R, Pearce DJ, Balkrishnan R et al. Critical factors determining the potency of topical corticosteroids. J Dermatolog. Treat. 2006;17:133-5.
15. Feldman SR, Horn EJ, Balkrishnan R et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009-16.
16. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-4.
17. Jemec GBE, Wulf HC. The greasiness of moisturizers: a methodological study. J. Cosmet. Surg. 1998;49:175-81.
18. Hol K. Patient preference for topical psoriasis formulations. Poster presented at the EADV Congress, Gothenburg, Sweden, 6-10 October. 2010.